CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Eltrombopag olamine

Last Updated: April 26, 2011
Result type: Reports
Project Number: S0230
Product Line: Common Drug Review

Generic Name: Eltrombopag olamine

Brand Name: Revolade

Manufacturer: GlaxoSmithKline

Indications: Thrombocytopenic purpura chronic immune (idiopathic)

Submission Type: New

Project Status: Complete

Date Recommendation Issued: October 24, 2011

Recommendation Type: Do not list